Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Arg-dmt-lys-phe-nh2
2. Arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide
3. Bendavia
4. D-arg-dmt-lys-phe-nh2
5. Mtp-131
6. Ss-31 Peptide
7. Ss31 Peptide
1. 736992-21-5
2. Bendavia
3. Mtp-131
4. Ocuvia
5. Mtp 131
6. Rx 31
7. Ss 31
8. L-phenylalaninamide, D-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-
9. Unii-87gwg91s09
10. Szeto-schiller Peptide
11. Rx-31
12. Ss-31
13. Nh2-d-arg-dmt-lys-phe-nh2
14. 87gwg91s09
15. D-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide
16. (2s)-6-amino-2-[[(2s)-2-[[(2r)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]amino]-n-[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]hexanamide
17. (s)-6-amino-n-((s)-1-amino-1-oxo-3-phenylpropan-2-yl)-2-((s)-2-((r)-2-amino-5-guanidinopentanamido)-3-(4-hydroxy-2,6-dimethylphenyl)propanamido)hexanamide
18. Ss-31 Peptide
19. Arg-dmt-lys-phe-nh2
20. D-arg-dmt-lys-phe-nh2
21. Ss31 Peptide
22. Elamipretide [inn]
23. Elamipretide [usan:inn]
24. Elamipretide (usan/inn)
25. Elamipretide [usan]
26. Elamipretide (mtp-131)
27. Elamipretide [who-dd]
28. Arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide
29. Chembl3833370
30. Schembl15028020
31. Dtxsid50471988
32. Ss-31mtp-131
33. Hy-p0125
34. S9803
35. Zinc43130902
36. Cs-5846
37. Db11981
38. D10925
39. D78262
40. A901134
41. Q27269822
| Molecular Weight | 639.8 g/mol |
|---|---|
| Molecular Formula | C32H49N9O5 |
| XLogP3 | 0 |
| Hydrogen Bond Donor Count | 9 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 19 |
| Exact Mass | 639.38566570 g/mol |
| Monoisotopic Mass | 639.38566570 g/mol |
| Topological Polar Surface Area | 267 Ų |
| Heavy Atom Count | 46 |
| Formal Charge | 0 |
| Complexity | 991 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 4 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Elamipretide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Elamipretide, including repackagers and relabelers. The FDA regulates Elamipretide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Elamipretide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Elamipretide supplier is an individual or a company that provides Elamipretide active pharmaceutical ingredient (API) or Elamipretide finished formulations upon request. The Elamipretide suppliers may include Elamipretide API manufacturers, exporters, distributors and traders.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Elamipretide as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Elamipretide API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Elamipretide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Elamipretide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Elamipretide NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Elamipretide suppliers with NDC on PharmaCompass.
Elamipretide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Elamipretide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Elamipretide GMP manufacturer or Elamipretide GMP API supplier for your needs.
A Elamipretide CoA (Certificate of Analysis) is a formal document that attests to Elamipretide's compliance with Elamipretide specifications and serves as a tool for batch-level quality control.
Elamipretide CoA mostly includes findings from lab analyses of a specific batch. For each Elamipretide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Elamipretide may be tested according to a variety of international standards, such as European Pharmacopoeia (Elamipretide EP), Elamipretide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Elamipretide USP).
LOOKING FOR A SUPPLIER?
